FrancophonIA/ELRC3.0 huggingface dataset:
English: The SPS study was a placebo-controlled, double-blind clinical trial in which 38,546 subjects were randomised to receive a single dose of either ZOSTAVAX or placebo and were followed for the development of zoster for a median of 3.1 years (range 31 days to 4.9 years).
Croatian: Ispitivanje prevencije herpes zostera (SPS) u ispitanika u dobi od 60 godina i starijih: Ispitivanje SPS bilo je placebom kontrolirano, dvostruko slijepo kliničko ispitivanje, u kojem je 38 546 ispitanika randomizirano u skupine koje su primile jednokratnu dozu cjepiva ZOSTAVAX ili placeba i praćene zbog razvoja herpes zostera tijekom medijana od 3,1 godine (raspon: od 31 dana do 4,9 godina).
English: One or 2 separate needles may be available in the packaging of the presentation containing the pre-filled syringe without attached needle.
Croatian: Jedna ili 2 zasebne igle mogu biti priložene u pakiranju koje sadrži napunjenu štrcaljku bez pričvršćene igle.
English: Monosodium L-glutamate monohydrate Disodium phosphate Sodium hydroxide (to adjust pH) Urea
Croatian: Prašak: saharoza hidrolizirana želatina natrijev klorid kalijev dihidrogenfosfat kalijev klorid natrijev L-glutamat hidrat natrijev hidrogenfosfat natrijev hidroksid (za podešavanje pH) urea
English: Inject the entire content of the syringe into the vial containing the powder.
Croatian: Ubrizgajte cijeli sadržaj štrcaljke u bočicu s praškom.
English: Inject the entire content of the pre-filled syringe into the vial containing the powder.
Croatian: Ubrizgajte cijeli sadržaj napunjene štrcaljke u bočicu s praškom.
English: Adverse reaction terms
Croatian: Način primjene
English: You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this vaccine.
Croatian: Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V.
English: The need for, or timing of, a booster dose with ZOSTAVAX has not yet been determined.
Croatian: Još nije utvrđeno je li potrebno docjepljivanje cjepivom ZOSTAVAX i kada to učiniti.
English: Withdraw the entire volume of solvent into a syringe.
Croatian: Izvucite cjelokupni volumen otapala u štrcaljku.
English: Powder and solvent for suspension for injection in a pre-filled syringe 1 vial (powder) + 1 pre-filled syringe without needle (solvent) 10 vials (powder) + 10 pre-filled syringes without needle (solvent) 20 vials (powder) + 20 pre-filled syringes without needle (solvent)
Croatian: Prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki 1 bočica (prašak) + 1 napunjena štrcaljka bez igle (otapalo) 10 bočica (prašak) + 10 napunjenih štrcaljki bez igle (otapalo) 20 bočica (prašak) + 20 napunjenih štrcaljki bez igle (otapalo)
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe with 2 unattached needles - Pack of 1, 10, 20
Croatian: ZOSTAVAX - prašak u bočici i otapalo u napunjenoj štrcaljki s 2 nepričvršćene igle - pakiranje od 1, 10, 20
English: Arthralgia, Myalgia, Pain in extremity
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva artralgija, mialgija, bol u ekstremitetu često
English: ZOSTAVAX - Powder in vial and solvent in vial - Pack of 1, 10
Croatian: ZOSTAVAX - prašak u bočici i otapalo u bočici - pakiranje od 1, 10
English: Shingles is a painful, blistering rash.
Croatian: Herpes zoster je bolni osip u obliku mjehurića.
English: VZV was detected in one (0.01%) specimen from a ZOSTAVAX recipient reporting a varicella/varicella-like rash; however, the virus strain (wild type or Oka/Merck strain) could not be determined.
Croatian: VZV je bio otkriven u jednom (0,01%) od uzoraka iz skupine ispitanika koji su primili ZOSTAVAX i prijavili osip vodenih kozica/nalik vodenim kozicama; međutim, soj virusa (divlji tip ili soj Oka/Merck) nije se mogao utvrditi.U svim drugim kliničkim ispitivanjima soj Oka/Merck bio je utvrđen PCR analizom u uzorcima iz lezija samo dva ispitanika koji su prijavili osip nalik vodenim kozicama (s nastupom 8. i 17. dana).
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe without needle - Pack of 1, 10, 20
Croatian: ZOSTAVAX - prašak u bočici i otapalo u napunjenoj štrcaljki bez igle - pakiranje od 1, 10, 20
English: VIAL OF POWDER
Croatian: BOČICA S PRAŠKOM
English: The VZV specific immune responses to ZOSTAVAX at Week 4 post-vaccination were comparable whether administered by SC or IM route.
Croatian: Specifičan imunološki odgovor protiv virusa varicella-zoster nastao na ZOSTAVAX u 4. tjednu nakon cijepljenja s.c. putem bio je usporediv s onim nakon cijepljenja i.m. putem.
English: Transmission of vaccine virus from varicella vaccine recipients who do not develop a varicella-like rash has also been reported.
Croatian: Prijavljen je i prijenos virusa iz cjepiva s osoba koje su bile cijepljene protiv vodenih kozica a nisu razvile osip sličan vodenim kozicama.
English: Disease information on shingles:
Croatian: Podaci o bolesti herpes zoster:
English: EU/1/06/341/005 - pack of 1 EU/1/06/341/006 - pack of 10 EU/1/06/341/007 - pack of 20
Croatian: EU/1/06/341/005 - pakiranje od 1 EU/1/06/341/006 - pakiranje od 10 EU/1/06/341/007 - pakiranje od 20
English: EU/1/06/341/008 - pack of 1 EU/1/06/341/009 - pack of 10 EU/1/06/341/010 - pack of 20
Croatian: EU/1/06/341/008 - pakiranje od 1 EU/1/06/341/009 - pakiranje od 10 EU/1/06/341/010 - pakiranje od 20
English: EU/1/06/341/003 - pack of 1 EU/1/06/341/004 - pack of 10
Croatian: EU/1/06/341/003 - pakiranje od 1 EU/1/06/341/004 - pakiranje od 10
English: It is unknown whether VZV is secreted in human milk.
Croatian: Nije poznato izlučuje li se virus varicella-zoster u majčino mlijeko.
English: Number of zoster cases
Croatian: Broj slučajeva herpes zostera
English: EU/1/06/341/001 - pack of 1 EU/1/06/341/002 - pack of 10
Croatian: EU/1/06/341/001 - pakiranje od 1 EU/1/06/341/002 - pakiranje od 10
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and needle shield (natural rubber), in a pack size of 1 or 10.
Croatian: Prašak u bočici (staklo) s čepom (butil guma) i "flip off" zatvaračem (aluminij) i otapalo u napunjenoj štrcaljki (staklo) s čepom klipa (klorbutil guma) i štitnikom za iglu (prirodna guma), u veličini pakiranja od 1 ili 10.
English: Powder and solvent for suspension for injection in a pre-filled syringe 1 vial (powder) + 1 pre-filled syringe with needle (solvent) 10 vials (powder) + 10 pre-filled syringes with needle (solvent)
Croatian: Prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki 1 bočica (prašak) + 1 napunjena štrcaljka s iglom (otapalo) 10 bočica (prašak) + 10 napunjenih štrcaljki s iglom (otapalo)
English: Powder and solvent for suspension for injection 1 vial (powder) + 1 vial (solvent) 10 vials (powder) + 10 vials (solvent)
Croatian: Prašak i otapalo za suspenziju za injekciju 1 bočica (prašak) + 1 bočica (otapalo) 10 bočica (prašak) + 10 bočica (otapalo)
English: U.S.A.
Croatian: A.
English: PRE-FILLED SYRINGE OF SOLVENT
Croatian: NAPUNJENA ŠTRCALJKA S OTAPALOM
English: EU/1/06/341/012 - pack of 10 EU/1/06/341/013- pack of 20
Croatian: EU/1/06/341/011 - pakiranje od 1 EU/1/06/341/012 - pakiranje od 10 EU/1/06/341/013 - pakiranje od 20
English: Varicella, Herpes zoster (vaccine strain)
Croatian: Infekcije i infestacije vodene kozice, herpes zoster (soj cjepiva)
English: HIV-infected adults with conserved immune function In a clinical trial, ZOSTAVAX was administered to HIV-infected adults (18 years of age or older, CD4+ T cell count ≥ 200 cells/µL) (see section 5.1).
Croatian: U kliničkom ispitivanju, ZOSTAVAX je bio primijenjen odraslima zaraženima HIV-om (u dobi od 18 godina ili starijima, s brojem CD4+
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadiene rubber) with one or two unattached needles in a pack size of 1, 10 or 20.
Croatian: Prašak u bočici (staklo) s čepom (butil guma) i "flip off" zatvaračem (aluminij) i otapalo u napunjenoj štrcaljki (staklo) s čepom klipa (klorbutil guma) i zatvaračem vrha (stiren butadien guma) s jednom ili dvije nepričvršćene igle, u veličini pakiranja od 1, 10 ili 20.
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (glass) with a stopper (chlorobutyl rubber) and flip off cap (aluminium) in a pack size of 1 or 10.
Croatian: Prašak u bočici (staklo) s čepom (butil guma) i "flip off" zatvaračem (aluminij) i otapalo u bočici (staklo) s čepom (klorobutil guma) i "flip off" zatvaračem (aluminij) u veličini pakiranja od 1 ili 10.
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe with attached needle Pack of 1,
Croatian: ZOSTAVAX - prašak u bočici i otapalo u napunjenoj štrcaljki s pričvršćenom iglompakiranje od 1, 10
English: ZOSTAVAX significantly reduced the zoster pain Burden of Illness (BOI) score (see Table 5).
Croatian: Burden of Illness, BOI) za mjerenje boli prouzročene herpes zosterom (vidjeti tablicu 5).
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadiene rubber) without needle in pack size of 1, 10 or 20.
Croatian: Prašak u bočici (staklo) s čepom (butil guma) i "flip off" zatvaračem (aluminij) i otapalo u napunjenoj štrcaljki (staklo) s čepom klipa (klorbutil guma) i zatvaračem vrha (stiren butadien guma) bez igle, u veličini pakiranja od 1, 10 ili 20.
English: Withdraw the entire contents of the solvent vial into a syringe.
Croatian: Izvucite cijeli sadržaj bočice s otapalom u štrcaljku.
English: Injection site: Erythema
Croatian: Opći poremećaji i reakcije na mjestu primjene mjesto injekcije: eritem
English: ZOSTAVAX powder and solvent for suspension for injection shingles (herpes zoster) vaccine (live)
Croatian: ZOSTAVAX prašak i otapalo za suspenziju za injekciju cjepivo protiv herpes zostera (živo)
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe with one unattached needle - Pack of 1, 10, 20
Croatian: ZOSTAVAX - prašak u bočici i otapalo u napunjenoj štrcaljki s jednom zasebnom iglompakiranje od 1, 10, 20
English: ZOSTAVAX powder and solvent for suspension for injection ZOSTAVAX powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live)
Croatian: ZOSTAVAX Prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki cjepivo protiv herpes zostera (živo)
English: ZOSTAVAX powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live)
Croatian: ZOSTAVAX prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki cjepivo protiv herpes zostera (živo)
English: , Pain/tenderness
Croatian: , bol/osjetljivost na dodir
English: All patients were receiving standard treatment.
Croatian: Svi su bolesnici primali standardno liječenje.
English: Cablivi (caplacizumab)
Croatian: Cablivi (kaplacizumab)
English: Treatment with Cablivi may continue for longer if necessary.
Croatian: Liječenje lijekom Cablivi može se nastaviti i dulje ako je potrebno.
English: Patients also receive treatments to reduce the immune system's activity.
Croatian: Bolesnici također primaju liječenje za smanjenje aktivnosti imunosnog sustava.
English: Patients or their carers may be able to inject Cablivi themselves after appropriate training.
Croatian: Bolesnici ili njihovi njegovatelji mogu sami davati lijek Cablivi nakon odgovarajuće obuke.
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
Croatian: Više informacija o statusu lijeka za rijetke bolesti možete pronaći ovdje: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
English: Further information on Cablivi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Cablivi nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The most important side effect of treatment is bleeding but it is considered manageable.
Croatian: Najvažnija nuspojava liječenja je krvarenje, no smatra se da to može kontrolirati.
English: What measures are being taken to ensure the safe and effective use of Cablivi?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Cablivi?
English: The most common side effects with Cablivi (which may affect more than 1 in 10 people) are nosebleeds, headache and bleeding from gums.
Croatian: Najčešće nuspojave lijeka Cablivi (mogu se pojaviti u više od 1 na 10 osoba) su krvarenje iz nosa, glavobolja i krvarenje iz desni.
English: The company that markets Cablivi will provide materials, including a patient alert card, on the risk of serious bleeding and how the risk should be managed.
Croatian: Tvrtka koja lijek Cablivi stavlja na tržište dostavit će materijale, uključujući karticu s upozorenjima za bolesnika, o rizicima od ozbiljnog krvarenja te o načinu upravljanja takvim rizicima.
English: What are the risks associated with Cablivi?
Croatian: Koji su rizici povezani s lijekom Cablivi?
English: Other information about Cablivi
Croatian: Ostale informacije o lijeku Cablivi
English: Side effects reported with Cablivi are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Cablivi pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cablivi have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Cablivi također se nalaze u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Cablivi is used together with plasma exchange (in which certain antibodies are removed from the blood) and treatments to reduce the activity of the immune system (the body's defences).
Croatian: Cablivi se upotrebljava zajedno s izmjenom plazme (tijekom koje se određena protutijela uklanjaju iz krvi) i liječenjima za smanjenje aktivnosti imunosnog sustava (obrane organizma).
English: For more information about using Cablivi, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Cablivi pročitajte u uputi o lijeku ili se obratite liječniku ili ljekarniku.
English: Treatment should be started and supervised by doctors experienced in managing patients who have clotting disorders affecting small blood vessels.
Croatian: Liječenje trebaju započeti i nadgledati liječnici iskusni u liječenju bolesnika s poremećajima zgrušavanja koji zahvaćaju male krvne žile.
English: What is Cablivi and what is it used for?
Croatian: Što je Cablivi i za što se primjenjuje?
English: The company is expected to provide results of a study on Cablivi's safety and effectiveness over a longer period.
Croatian: Od tvrtke se očekuje da dostavi rezultate ispitivanja sigurnosti primjene i učinkovitosti lijeka Cablivi tijekom dužeg razdoblja liječenja.
English: The European Medicines Agency decided that Cablivi's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove odlučila je da koristi lijeka Cablivi nadmašuju s njim povezane rizike te da se može izdati odobrenje za njegovu primjenu u EU-u.
English: Why is Cablivi authorised in the EU?
Croatian: Zašto je lijek Cablivi odobren u EU-u?
English: As for all medicines, data on the use of Cablivi are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Cablivi kontinuirano se prate.
English: Cablivi can only be obtained with a prescription.
Croatian: Cablivi se izdaje samo na liječnički recept.
English: During an episode of aTTP, blood clots form in small blood vessels and the patient has a low count of platelets (components that help the blood to clot).
Croatian: Tijekom epizode aTTP-a stvaraju se krvni ugrušci u malim krvnim žilama i bolesnik ima malen broj trombocita (krvne pločice koje pomažu u zgrušavanju krvi).
English: Treatment is continued with 10 mg daily given by injection under the skin in the belly after daily plasma exchange and continued for 30 days after daily plasma exchange is stopped.
Croatian: Liječenje se nastavlja dozom od 10 mg dnevno, koja se daje potkožnom injekcijom u trbuh nakon svakodnevne izmjene plazme, te traje 30 dana nakon prekida svakodnevne izmjene plazme.
English: An overview of Cablivi and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Cablivi i zašto je odobren u EU-u
English: In the first study, involving 75 patients, platelet counts returned to the normal range after 3 days on average in patients treated with Cablivi, compared with nearly 5 days in those receiving placebo (a dummy treatment).
Croatian: U prvom ispitivanju, u kojem je sudjelovalo 75 bolesnika, broj trombocita vratio se u normalan raspon nakon prosječno tri dana u bolesnika liječenih lijekom Cablivi, u usporedbi s gotovo pet dana u onih kojih su primali placebo (prividno liječenje).
English: The Agency considered that, in patients with aTTP, Cablivi combined with plasma exchange and immunosuppression can reduce the time it takes for platelet counts to return to the normal range, which is associated with shorter duration of plasma exchange treatment and shorter stay in intensive care facility.
Croatian: Agencija je smatrala da u bolesnika sa stečenom trombotičnom trombocitopeničnom purpurom lijek Cablivi, u kombinaciji s izmjenom plazme i imunosupresijom, može skratiti vrijeme potrebno za povrat broj trombocita na normalnu razinu, što je povezano s kraćim trajanjem liječenja izmjenom plazme i kraćim boravkom na odjelu intenzivne njege.
English: This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
Croatian: Tako se smanjuje sljepljivanje trombocita i stvaranje krvnih ugrušaka u krvnim žilama što za posljedicu ima povišenje razina trombocita u krvi jer oni više ne stvaraju ugruške.
English: Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets.
Croatian: Kaplacizumab, djelatna tvar u lijeku Cablivi, jest nanotijelo (malo protutijelo) koje je osmišljeno kako bi se spajalo na von Willebrandov faktor i time zaustavilo njegovo djelovanje na trombocite.
English: The second study, involving 145 patients, measured how long it took for the platelet count to return to the normal range and for sufficient improvement in the condition to allow daily plasma exchange to be stopped within 5 days.
Croatian: U drugom se ispitivanju, u kojem je sudjelovalo 145 bolesnika, mjerilo koliko je vremena bilo potrebno za povrat broja trombocita u normalan raspon te za dovoljno poboljšanje bolesti kako bi se svakodnevne izmjene plazme mogle prekinuti u roku od pet dana.
English: von Willebrand factor acts on platelets to cause them to stick together and form blood clots.
Croatian: Von Willebrandov faktor djeluje na trombocite i dovodi do njihova sljepljivanja i stvaranja krvnih ugrušaka.
English: How is Cablivi used?
Croatian: Kako se Cablivi koristi?
English: In patients with aTTP, levels of a substance called von Willebrand factor are increased.
Croatian: U bolesnika sa stečenom trombotičnom trombocitopeničnom purpurom povišene su razine tvari koja se naziva von Willebrandov faktor.
English: Cablivi is started with a dose of 10 mg given by injection into a vein before plasma exchange.
Croatian: Početna doza lijeka Cablivi je 10 mg i daje se injekcijom u venu prije izmjene plazme.
English: What benefits of Cablivi have been shown in studies?
Croatian: Koje su koristi od lijeka Cablivi utvrđene u ispitivanjima?
English: aTTP is rare, and Cablivi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 April 2009.
Croatian: Stečena trombotična trombocitopenična purpura rijetka je bolest, a lijek Cablivi dobio je status lijeka za rijetku bolest 30. travnja 2009.
English: The study found that platelet count was likely to return to the normal range more quickly in patients treated with Cablivi compared with those receiving placebo.
Croatian: U ispitivanju je zaključeno da će se broj trombocita vjerojatno vratiti u normalan raspon brže u bolesnika liječenih lijekom Cablivi nego u onih liječenih placebom.
English: For the full list of side effects and restrictions with Cablivi, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Cablivi potražite u uputi o lijeku.
English: How does Cablivi work?
Croatian: Kako djeluje Cablivi?
English: Cablivi is a medicine used for treating adults who have an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a blood clotting disorder.
Croatian: Acquired Thrombotic Thrombocytopenic Purpura - aTTP), što je poremećaj zgrušavanja krvi.
English: Two main studies have investigated the effectiveness of Cablivi in patients with aTTP who required plasma exchange to treat their condition.
Croatian: Učinkovitost lijeka Cablivi ispitana je u dvama glavnim ispitivanjima u bolesnika sa stečenom trombotičnom trombocitopeničnom purpurom koji su morali biti liječeni izmjenom plazme.
English: Cablivi contains the active substance caplacizumab.
Croatian: Cablivi sadržava djelatnu tvar kaplacizumab.
English: Date of first authorisation: 22 November 2018
Croatian: Datum prvog odobrenja: 22. studenog 2018.
English: • This medicine can be taken with food or between meals.
Croatian: • Ovaj se lijek može uzimati s hranom ili između obroka.
English: Blood tests may also show:
Croatian: Krvne pretrage mogu pokazati i:
English: Talk to your doctor about what you can do to avoid infecting other people.
Croatian: Razgovarajte sa svojim liječnikom o tome što možete učiniti da ne biste zarazili druge osobe.
English: 3; these characteristics were similar between treatment groups.
Croatian: 3; te su značajke bile slične u obje liječene skupine.
English: Parameter GM ( %CV)
Croatian: Parametar GM (% CV)
English: Do not stop taking this medicine without first talking to your doctor.
Croatian: Nemojte prestati uzimati ovaj lijek bez prethodnog razgovora sa svojim liječnikom.
English: Discuss your hepatitis B therapy with your doctor.
Croatian: Razgovarajte o svojoj terapiji za hepatitis B sa svojim liječnikom.
English: Talk with your doctor about the best way to feed your baby.
Croatian: Posavjetujte se sa svojim liječnikom o najboljem načinu prehrane za svoje dijete.
English: It belongs to a group of medicines called ‘antiretroviral medicines'.
Croatian: Pripada skupini lijekova koji se zovu „antiretrovirusni lijekovi“.
English: The clinical relevance of this finding is unknown.
Croatian: Klinički značaj tog nalaza nije poznat.
English: Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time.
Croatian: Vaš imunološki sustav može ojačati i početi se boriti protiv infekcija koje su dugo vremena bile prikrivene u Vašem tijelu.
English: A similar effect was not seen in rats even at very high systemic exposure.
Croatian: Sličan učinak nije zapažen u štakora čak ni pri vrlo visokim razinama sistemske izloženosti.
English: Your doctor may need to do additional tests to check your bones.
Croatian: Vaš će liječnik možda morati provesti dodatne pretrage kako bi provjerio stanje Vaših kostiju.
English: The recommended dose is 1 tablet once a day.
Croatian: Preporučena je doza 1 tableta jedanput na dan.
English: The patient should not take 2 doses at one time.
Croatian: Bolesnik ne smije uzeti 2 doze odjednom.